Articles

The IOPtiMate laser-based system, from the Bio-Light Group, used for the non-invasive filtration treatment of glaucoma has received European Patent Office approval.

The NAVILAS laser system, as reported on in the OTE Digest back in May this year ( What is Retinal Navigation? ) has been given FDA approval.

Lumenis is to undertake a clinical study into the efficacy of selective retina therapy (SRT) in diabetic macular oedema (DME).

Ellex Medical Lasers Ltd. unveiled the latest version of its diagnostic ultrasound system (Eye Cubed) at the recent annual meeting of the American Academy of Ophthalmology.

Adrienne Graves, CEO of Santen Inc., has been appointed to the Glaucoma Research Foundation?s board of directors.

An accommodating lens has the potential to provide functional vision at all distances in a seamless continuum and overcome dysphotopsias.

One surgeon's preference for an ophthalmic viscosurgical device of 1.6% sodium hyaluronate was reinforced by a study that found it superior to another OVD during phaco and OVD removal

The fusion of imaging technology for today and tomorrow to assess your patients' retinal health

Professor Mats Lundstrom, chairman of EUREQUO, talks to OTE about the project and its dissemination in Europe.

Taking the first step towards analysing your career goals and the return on your investment.

Hyperaemia is one of the main reasons why patients with glaucoma do not comply with or persist with their topical therapeutic regimen.

A new hypothesis about the development of AMD points to a role of age-depleted steroidal hormones. An ophthalmologist discusses the evidence supporting this idea.

Participants in a survey showed low awareness that this option was available for patients with glaucoma.

For now, the most effective way to prevent or manage diabetic retinopathy is taking a proactive approach to controlling blood glucose levels and hypertension in patients.

A proprietary phacoemulsification system featuring fluidics control software that allows automatic switching from longitudinal ultrasound to transversal on recognition of occulsion and back again to longitudinal on occlusion break.

A new bimanual capsulorhexis technique, suing a specially developed instrument allowing a tri-dimensional, sub 1mm capsulorhexis with improved maintenance of the anterior chamber.

In the second of a two-part article Dr David Tanzer says that in today's US Navy the preferred refractive procedure today is wavefront-guided LASIK with a thin flap made with a femtosecond laser.

The fusion of imaging technology for today and tomorrow to assess your patient's retinal health

The German-based company VRmagic has introduced an augmented reality simulator for the training of binocular indirect ophthalmoscopy.

Reports presented at the American Academy of Ophthalmology (AAO) conference suggest that doctors may be able to assist in predicting Alzheimer's disease.

“It is time for paediatric ophthalmologists to reassess how best to screen and treat their smallest, frailest patients,” said Dr. John Flynn of Columbia University School of Medicine, speaking at the Paediatric Ophthalmology symposium, being held alongside the AAO in San Francisco.

Allergan Inc. has won a ruling in federal court that its patents on Alphagan, which lowers pressure in the eye in patients with open-angle glaucoma and ocular hypertension, were infringed.

STAAR Surgical Company has reported that the Collamer Accommodating Study Team (CAST) formed by the company in late 2008 has provided very promising initial patient vision assessments from the first phase of the project.

Real-time biomedical studies of factors leading to vision impairment are now possible through one of the world's largest ocular research centre at Lions Eye Institute for Transplant & Research.

In Ophthalmology V Borderie et al., analyze graft survival and the outcome of the corneal endothelium after corneal transplantation in a single model to predict the long-term prognosis of these grafts

Two Phase III studies of Lucentis (ranibizumab injection) in macular oedema due to retinal vein occlusion (RVO), have shown, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections. Results from both trials were presented at the Retina Congress 2009 meeting.

According to M Rekas et al., in The Journal of Cataract & Refractive Surgery torsional phacoemulsification was found to be more effective than longitudinal phacoemulsification in the amount of applied fluid and the quantity of US energy expended.

Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).

According to the Review of OphthalmologyRefinements in tools and technique are leading to better outcomes, fewer complications and promising new versions of the surgery.